Product Data Sheet

Brilliant Violet 750™ anti-human CD19

Catalog # / 2111310 / 100 tests

Size: 2111305 / 25 tests

Clone: HIB19

Isotype: Mouse IgG1, κ

Reactivity: Human, Non-human primate

Preparation: The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 750™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 750™

and unconjugated antibody.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

BSA (origin USA).

Workshop Number: V CD19.11

Concentration: Lot-specific



Human peripheral blood lymphocytes stained with CD19 (clone HIB19) Brilliant Violet 750™ (filled histogram) or Mouse IgG1, κ Brilliant Violet 750™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood.

volume of 5 µl per 100 µl of whole brood.

Brilliant Violet 750™ excites at 405 nm and emits at 750 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 750™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:

Additional reported applications (for the relevant formats) include:

immunohistochemical staining of acetone-fixed frozen tissue sections⁸ and blocking of B cell proliferation. Clone HIB19 is not recommended for

formalin-fixed paraffin-embedded sections.

Application References:

- 1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
- 2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- 3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
- 4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
- 5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
- 6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
- 7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
- 9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
- 10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)

Description: CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a

member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as

a BCR co-receptor.

Antigen References: 1. Tedder T, et al. 1994. Immunol. Today 15:437.

2. Bradbury L, et al. 1993. J. Immunol. 151:2915.